Lundbeck unveils migraine data for eptinezumab at international congress
Written by
PharmaTimes
Published
0
comments
0
min
New phase 4 results show sustained symptom relief and improved patient outcomes New phase 4 results show sustained symptom relief and improved patient outcomes